Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Brii Bio In-licenses China Rights to Second HBV mAb from Vir

publication date: Jul 5, 2022

Beijing’s Brii Biosciences exercised an option to acquire China rights to a neutralizing monoclonal antibody for HBV from Vir Biotechnology. Brii is currently testing a combination of two Vir assets with the goal of offering a functional cure for HBV. It now owns China rights to both candidates. In a US Phase II trial, Vir showed that the combination of the two molecules offers a better response than either one alone. In 2018, Brii was formed with $260 million in initial capital and options on four Vir infectious disease therapies. More details...

Stock Symbol: (HK: 2137)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here